J D Miller1. 1. Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Rockford, 61107, USA.
Abstract
OBJECTIVE: The purpose of this study was a quantification of changes in endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy. STUDY DESIGN: One hundred twenty women with significant endometriosis-associated pain participated in a 1-month double-blind, randomized, placebo-controlled trial. Pain was measured at baseline and at 2 and 4 weeks with visual analog scales and the Endometriosis Symptom Severity score. Quality of life was measured with the SF-36 instrument. Group means and SEMs were calculated. Paired t tests were used after determination of data normality. RESULTS: Compared with placebo-treated control subjects women treated with gonadotropin-releasing hormone agonist had a statistically (P <. 0001) and clinically significant temporary increase in pain and a concomitant decrease in quality of life. CONCLUSION: The stimulatory phase of gonadotropin-releasing hormone agonist therapy is associated with an increase in endometriosis-associated pain and a decrease in quality of life.
RCT Entities:
OBJECTIVE: The purpose of this study was a quantification of changes in endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy. STUDY DESIGN: One hundred twenty women with significant endometriosis-associated pain participated in a 1-month double-blind, randomized, placebo-controlled trial. Pain was measured at baseline and at 2 and 4 weeks with visual analog scales and the Endometriosis Symptom Severity score. Quality of life was measured with the SF-36 instrument. Group means and SEMs were calculated. Paired t tests were used after determination of data normality. RESULTS: Compared with placebo-treated control subjects women treated with gonadotropin-releasing hormone agonist had a statistically (P <. 0001) and clinically significant temporary increase in pain and a concomitant decrease in quality of life. CONCLUSION: The stimulatory phase of gonadotropin-releasing hormone agonist therapy is associated with an increase in endometriosis-associated pain and a decrease in quality of life.
Authors: Peter M Wayne; Catherine E Kerr; Rosa N Schnyer; Anna T R Legedza; Jacqueline Savetsky-German; Monica H Shields; Julie E Buring; Roger B Davis; Lisa A Conboy; Ellen Highfield; Barbara Parton; Phaedra Thomas; Marc R Laufer Journal: J Pediatr Adolesc Gynecol Date: 2008-10 Impact factor: 1.814
Authors: Donald E Stull; Radek Wasiak; Noemi Kreif; Mireia Raluy; Antje Colligs; Christian Seitz; Christoph Gerlinger Journal: Qual Life Res Date: 2013-07-13 Impact factor: 4.147
Authors: Mauricio S Abrao; Eric Surrey; Keith Gordon; Michael C Snabes; Hui Wang; Horia Ijacu; Hugh S Taylor Journal: BMC Womens Health Date: 2021-06-16 Impact factor: 2.809